ORIGINAL RESEARCH article
Front. Oncol.
Sec. Pediatric Oncology
Promising Outcomes of R-CHOP Therapy in Pediatric Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Perspectives from a Rare Subtype
Nesreen Ali 1
Eman Khorshed 2
Mohamed S Zaghloul 3
Maha Mehsen 4
Sarah Badawy 5
walaa Elsayed 1
1. Department of Pediatric Oncology, National Cancer Institute, Cairo University, Egypt and Children’s Cancer Hospital Egypt 57357, cairo, Egypt
2. Department of Pathology, National Cancer Institute, Cairo University, Egypt and Children’s Cancer Hospital Egypt 57357, cairo, Egypt
3. Department of Radiation Oncology, National Cancer Institute, Cairo University, Egypt and Children’s Cancer Hospital Egypt 57357, cairo, Egypt
4. Department of Nuclear Medicine, National Cancer Institute, Cairo University, Egypt and Children’s Cancer Hospital Egypt 57357, cairo, Egypt
5. Department of Clinical research, Children’s Cancer Hospital Egypt 57357, cairo, Egypt
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare sub-type of Hodgkin lymphoma (HL). Due to its rarity, the standard of care for these patients remains poorly defined. Our cohort aimed to evaluate the outcomes of pediatric NLPHL patients treated with the R-CHOP regimen throughout 8 years' single center experience. Methods: A retrospective cohort study including pediatric patients aged <18 years diagnosed with NLPHL and treated at the Children Cancer Hospital Egypt, between July 2014 and June 2022. Results: In total, 66 patients were included. Twelve patients (18%) with stage IA underwent surgical excision alone. Four of these patients experienced disease progression but achieved a complete response after receiving R-CHOP. Fifty-four patients received R-CHOP as first-line therapy, with early-stage disease received 3-4 cycles, while those with advanced-stage disease received 6 cycles. For this group, the 5-year overall (OS) and event free survival (EFS) were 100% and 91.5%, respectively. The 5-year EFS was not significantly affected by the variant histology pattern among patients received R-CHOP. Patients with stage 3 peripheral disease without risk factors demonstrated outcomes comparable to those with early-stage disease and no risk factors, achieving an excellent 5-year EFS rate of 100%. No significant toxicity was reported, except for grade 3-4 neutropenia. Conclusion: R-CHOP is an effective and well-tolerated regimen for treating pediatric NLPHL, demonstrating high OS and EFS rates. Patients with early stage disease achieved particularly favorable outcomes, supporting consideration of treatment de-escalation in this subgroup.
Summary
Keywords
Event free survival, Nodular lymphocyte predominant Hodgkin lymphoma, outcomes, pediatric, R-CHOP
Received
05 November 2025
Accepted
20 February 2026
Copyright
© 2026 Ali, Khorshed, Zaghloul, Mehsen, Badawy and Elsayed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nesreen Ali; walaa Elsayed
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.